P511 Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01).

Douglas C. Wolf,James D. Lewis,Britta Siegmund,Gary R. Lichtenstein,Shaji Sebastian,Corey A. Siegel,Édouard Louis,T. Haas,K. Nedd,Sreedhar Subramanian,Humberto Aguilar,Laurence J. Egan,Christoph Gasche,Glen A. Doherty,Alan J. Lobo,D. Spearman,Amir C. Patel,R. Moparty,M. Brookes,Xavier Hébuterne,Bjørn Moum,P. Dolin

P511 Baseline characteristics of ulcerative colitis patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (01).

2017

Background: The aim of this study is to quantify and compare the safety and effectiveness of vedolizumab (VDZ) with other biologic agents (OBAs) in ulcerative colitis and Crohn's disease (CD). The study is currently recruiting 5,000 IBD patients across 23 countries in North America and Europe, and w

Keywords:

Physical therapy
Ulcerative colitis
Diabetes mellitus
Disease
Biologic Agents
Vedolizumab
Medicine
Cohort study
baseline characteristics
Interim analysis
hospital admission

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations